Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, Formerly NASDAQ:EYEG) Investor Notice: Investigation

An investigation was announced for investors in Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

San Diego, CA — (SBWIRE) — 02/15/2022 — An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

Investors who purchased shares of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG) concerning whether a series of statements by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Salt Lake City, UT based Kiora Pharmaceuticals, Inc., formerly EyeGate Pharmaceuticals, Inc.,, an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States.

Kiora Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $2.68 million in 2019 to $0.012 million in 2020, and that its Net Loss increased from $7.09 million in 2019 to $8.17 million in 2020.

Shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG) declined from over $12 per share in late 2019 to as low as $0.65 per share on January 27, 2022.

Those who purchased shares of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/kiora-pharmaceuticals-inc-eyegate-pharmaceuticals-inc-nasdaqkprx-1353208.htm

Media Relations Contact

Michael Daniels
Shareholders Foundation
Telephone: 1-858-779-1554
Email: Click to Email Michael Daniels
Web: https://www.shareholdersfoundation.com/